-
2023-505807-21-00
5
2021-11-16
Relapsed/refractory follicular lymphoma
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-508968-30-00
5
2021-09-08
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
-
2023-504716-15-00
6
2021-08-06
Psoriatic Arthritis
-
2024-511321-54-00
5
2021-08-04
intermediate-high-risk acute pulmonary embolism
-
2024-516868-28-00
4
2021-05-04
Ph+ Acute Lymphoblastic Leukemia
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2024-511637-35-00
5
2021-03-23
Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2024-512354-21-00
4
2021-02-22
Newly diagnosed multiple myeloma
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2024-513616-95-00
10
2020-12-22
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
-
2024-513296-41-00
4
2020-12-03
Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2023-503421-19-00
5
2020-08-26
Urothelial cancer
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2023-507419-37-00
5
2020-06-25
Plasma cell myeloma
-
2024-514079-17-00
10
2020-05-28
Endogenous Cushing Syndrome
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2023-505477-33-00
5
2019-06-18
Psoriatic Arthritis